306 related articles for article (PubMed ID: 36290837)
21. Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.
Tam CS; Kapoor P; Castillo JJ; Buske C; Ansell SM; Branagan AR; Kimby E; Li Y; Palomba ML; Qiu L; Shadman M; Abeykoon JP; Sarosiek S; Vos J; Yi S; Stephens D; Roos-Weil D; Roccaro AM; Morel P; Munshi NC; Anderson KC; San-Miguel J; Garcia-Sanz R; Dimopoulos MA; Treon SP; Kersten MJ
Semin Hematol; 2023 Mar; 60(2):118-124. PubMed ID: 37099031
[TBL] [Abstract][Full Text] [Related]
22. Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with
Zhu J; Zhu X; Xie F; Ding Y; Lu H; Dong Y; Li P; Fu J; Liang A; Zeng Y; Xiu B
Pathol Oncol Res; 2023; 29():1611070. PubMed ID: 37151353
[No Abstract] [Full Text] [Related]
23. Management of Waldenström Macroglobulinemia in Limited-Resource Settings.
Riva E; Tietsche de Moraes Hungría V; Chiattone C; Martínez-Cordero H
Hematol Oncol Clin North Am; 2023 Aug; 37(4):801-807. PubMed ID: 37258356
[TBL] [Abstract][Full Text] [Related]
24. Current options to manage Waldenström's macroglobulinemia.
Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
[TBL] [Abstract][Full Text] [Related]
25. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
26. Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia.
Tawfiq RK; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2024 Jun; 19(3):120-137. PubMed ID: 38536576
[TBL] [Abstract][Full Text] [Related]
27. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
[TBL] [Abstract][Full Text] [Related]
28. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.
Sermer D; Sarosiek S; Branagan AR; Treon SP; Castillo JJ
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):547-556. PubMed ID: 35339405
[TBL] [Abstract][Full Text] [Related]
29. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
Thomas SK
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
[TBL] [Abstract][Full Text] [Related]
30. Novel treatment options for Waldenström macroglobulinemia.
Leblebjian H; Agarwal A; Ghobrial I
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S310-6. PubMed ID: 24290218
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
Sekiguchi N
Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
[TBL] [Abstract][Full Text] [Related]
32. Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2021 Feb; 96(2):258-269. PubMed ID: 33368476
[TBL] [Abstract][Full Text] [Related]
33. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia.
Muñoz J; Paludo J; Sarosiek S; Castillo JJ
Cells; 2022 Oct; 11(20):. PubMed ID: 36291152
[TBL] [Abstract][Full Text] [Related]
34. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
35. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
37. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
38. High-Dose Therapy and Hematopoietic Stem Cell Transplantation in Waldenström Macroglobulinemia.
Kyriakou C
Hematol Oncol Clin North Am; 2018 Oct; 32(5):865-874. PubMed ID: 30190024
[TBL] [Abstract][Full Text] [Related]
39. Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2015 Apr; 90(4):346-54. PubMed ID: 25808108
[TBL] [Abstract][Full Text] [Related]
40. Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2011 May; 86(5):411-6. PubMed ID: 21523800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]